Literature DB >> 2537686

Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay.

P Tagari1, D Ethier, M Carry, V Korley, S Charleson, Y Girard, R Zamboni.   

Abstract

Leukotriene (LT) E4, an important LT metabolite appearing in urine, can be rapidly separated from normal and pathological urines by automated reversed-phase HPLC after a simple sample-processing. The recoveries of LTE4 afforded by this system (86.4 +/- 6.5%, mean +/- SEM for 60 ng/L, 85.4 +/- 0.3% for 200 ng/L) are superior to those obtained by a manual extraction method. Consistency of results is similar. Highly reproducible retention times combined with a radioimmunoassay allow one to identify (based on co-elution) and quantify as little as 8 ng/L LTE4 in a 10-mL urine sample. LTE4 concentrations in urine from healthy persons approach this value (17 +/- 5 ng/L), whereas samples from patients with cardiac ischemia show a wider range of concentrations (8 to 388 ng/L), up to 50 times the detection limit. Thus this method is applicable to the noninvasive investigation of leukotriene involvement in a wide range of ischemic, inflammatory, and hypersensitive conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537686

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.

Authors:  P Tagari; C Brideau; C Chan; R Frenette; C Black; A Ford-Hutchinson
Journal:  Agents Actions       Date:  1993-09

2.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.

Authors:  E Mayatepek; W D Lehmann; J Fauler; D Tsikas; J C Frölich; R B Schutgens; R J Wanders; D Keppler
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

3.  Enhancement of mass spectrometric detection of LTC4, LTD 4, and LTE 4 by derivatization.

Authors:  O A Mamer; G Just; C S Li; P Préville; S Watson; R Young; J A Yergey
Journal:  J Am Soc Mass Spectrom       Date:  1994-04       Impact factor: 3.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.